Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Megan Rigby
Observed name:
Rigby, Megan
Institutions:
Frederick National Laboratory for Cancer Research,
National Cancer Institute,
Leidos Biomedical Research Inc. (United States)
Observed institutions:
Frederick National Laboratory for Cancer Research,
National Cancer Institute,
Leidos Biomedical Research Inc. (United States)
ORCID:
0000-0002-4438-9797
Observed ORCID:
0000-0002-4438-9797
OpenAlex ID:
A5088334371
Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties
2024
·
Matthew J. Whitley
, Timothy H. Tran
, et al.
·
Science Advances
·
46
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
·
Cancer Discovery
·
12
Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine
2025
·
Anna E. Maciag
, Yue Yang
, et al.
·
Proceedings of the National Academy of Sciences
·
8
PDF
Solution NMR assignments of oncogenic G12C mutant of T35S-C118S KRAS4b-GppNHp
2026
·
Sharma, Alok
, Dyba, Marcin
, et al.
·
Biological Magnetic Resonance Bank
Solution NMR Assignments of oncogenic G12D mutant of T35S-C118S KRAS4b-GppNHp
2026
·
Sharma, Alok K.
, Dyba, Marcin
, et al.
·
Biological Magnetic Resonance Bank
Supplementary Figure S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S5 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Suppl. Materials and Methods 1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S7 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Table S2 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S4 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S8 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Table S3 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Table S1 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Supplementary Figure S6 from Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants
2026
·
Carlos Stahlhut
, Anna E. Maciag
, et al.
Show more works
View as search
Works count:
17
Citation count:
66
H-index:
3
I10-index:
2
Year
Topic
Type